Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Multiple Drug Resistance Bacterial Infection Treatment Market Forecasts to 2025 - Research and Markets

Research and Markets
Posted on: 11 Dec 17

The "Global Multiple Drug Resistance Bacterial Infection Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to Research and Markets' offering.

The global multiple drug resistance bacterial infection treatment market was valued at US$ 26,169.09 Mn in 2016, and is expected to reach US$ 44,060.77 Mn by 2025 expanding at a CAGR of 6.01% from 2017 to 2025.

Oxazolidinone and Glycolipopeptides will be the fastest-growing markets in the drug class segment throughout 2017-2025 majorly due to factors such as the large development gap in the antibiotic development and emergence of effective antibiotics such as Linezolid and Dalbavancin exhibiting improved pharmacodynamic activity and technological advancement in the rapid diagnostics testing kits.

High segment will be the fastest-growing segment for the vectors market throughout 2017-2025 majorly due to factors such as increasing number of patients suffering with Helicobacter pylori and Staphylococcus aureus infection and public-private partnerships in the diagnosis and antibiotics development to treat antimicrobial drug resistance.

In 2016, Beta Lactam held the largest market in the drug class segment due to factors such as rising prevalence of multiple drug resistance cases and development of drugs such as Ceftazidime-avibactam and Doripenem which exhibit broad spectrum activity to counteract drug resistance by bacteria.

Key Market Movements:

  • Rising prevalence of patients suffering with multiple drug resistance
  • Increasing public-private institutes partnership resulting into development of effective antibiotics to counter act MDR by microbes
  • Technological advancement in the rapid diagnostic kits providing better interpretation
  • Affordable reimbursement scenario

Key Topics Covered:

Chapter 1. Preface

Chapter 2. Executive Summary

Chapter 3. Multiple Drug Resistance Bacterial Infection Treatment Market: Market Dynamics and Future Outlook

Chapter 4. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Vector, 2015 - 2025 (US$ Mn)

Chapter 5. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Drug Class, 2015 - 2025 (US$ Mn)

Chapter 6. Global Multiple Drug Resistance Bacterial Infection Treatment Market, by Geography, 2015 - 2025 (US$ Mn)

Chapter 7. Company Profiles

  • Abbott Laboratories, Inc.
  • Actelion Pharmaceuticals Ltd.
  • Albany Molecular Research, Inc.
  • Allergan plc.
  • AstraZeneca
  • Bayer AG
  • Biocon
  • Daiichi Sankyo Company
  • GlaxoSmithKline plc.
  • Macrolide Pharmaceuticals, Inc.
  • Merck & Co, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/6gbrcv/global_multiple?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20171211006251/en/

Business Wire
www.businesswire.com

Last updated on: 11/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.